Immune Checkpoint Inhibitors in Melanoma and HIV Infection

Antonio Marra1, Giosuè Scognamiglio2, Ilaria Peluso3, Gerardo Botti2, Celeste Fusciello4, Amelia Filippelli5, Paolo A. Ascierto6, Stefano Pepe4, Francesco Sabbatino4, *
1 Department of Medical Oncology, San Gerardo Hospital, via G. B. Pergolesi, 20052 Monza, Italy
2 Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, via M. Semmola, 80131 Naples, Italy
3 Hematology Unit, Department of Clinical and Surgical Medicine, University of Naples Federico II, via S. Pansini, 80131 Naples, Italy
4 Oncology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, via Allende, 84081 Baronissi (Salerno), Italy
5 Pharmacology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, via Allende, 84081 Baronissi (Salerno), Italy
6 Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, via M. Semmola, 80131 Naples, Italy

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 513
Abstract HTML Views: 311
PDF Downloads: 685
ePub Downloads: 670
Total Views/Downloads: 2179
Unique Statistics:

Full-Text HTML Views: 364
Abstract HTML Views: 171
PDF Downloads: 141
ePub Downloads: 111
Total Views/Downloads: 787

© 2017 Marra et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Correspondence: Address correspondence to this author at the Department of Medicine Surgery and Dentistry, University of Salerno, 84081 Baronissi (Salerno), Italy; Tel: +39089672710; Fax: +39089672539; E-mail:



Immunotherapy with immune checkpoint inhibitors increases the overall survival of patients with metastatic melanoma regardless of their oncogene addicted mutations. However, no data is available from clinical trials of effective therapies in subgroups of melanoma patients that carry chronic infective diseases such as HIV. Evidences suggest a key role of the immune checkpoint molecules as a mechanism of immune escape not only from melanoma but also from HIV host immune response.


In this article, firstly, we will describe the role of the immune checkpoint molecules in HIV chronic infection. Secondly, we will summarize the most relevant clinical evidences utilizing immune checkpoint inhibitors for the treatment of melanoma patients. Lastly, we will discuss the potential implications as well as the potential applications of immune checkpoint molecule-based immunotherapy in patients with melanoma and HIV infection.

Keywords: Melanoma, HIV, Immunotherapy, Immune checkpoint molecules, Infection, Survival.


Melanoma is an aggressive form of skin cancer characterized by poor prognosis and high mortality. In Europe, about 100,000 new cases of melanoma are diagnosed every year and incidence of melanoma is continuously increasing [1]. Patients with immunodeficiency and especially those affected by Human Immunodeficiency Virus (HIV) chronic infection are characterized by a higher risk of tumor development including melanoma. The incidence of melanoma in HIV infected patients is 2.6 higher as compared to no HIV patients [2]. This increased incidence reflects both a decreased efficiency of the host immune response in eliminating potentially malignant cells and an improvement in the treatment of HIV patients because of the development of new antiretroviral agents. The latter prolong the survival of the infected patients [3] increasing the time of immunodeficiency and the possibility of tumor development. However, in HIV patients, melanoma shows a more aggressive phenotype and poorer survival outcomes as compared to non HIV patients [4]. Implementation of monoclonal antibodies (mAbs), inhibiting the interaction of immune suppressive checkpoint molecules with their ligands, has dramatically changed the clinical course of cancer patients, including those with melanoma. The administration of mAbs targeting immune checkpoint molecules such as Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) and Programmed Death-1 (PD-1) significantly increases overall survival (OS) of metastatic melanoma patients [5]. In addition, novel mAbs targeting different immune checkpoint molecules, such as Programmed Death Ligand-1 (PD-L1), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), Lymphocyte Activation Gene-3 (LAG-3) and T cell immunoreceptor with Ig and ITIM domains (TIGIT), are now being tested in promising clinical trials alone or in combination with CTLA-4 or PD-1 inhibitors. Nevertheless, scant information is available about the efficacy and safety of these therapeutic strategies in HIV infected melanoma patients. Indeed, HIV infected melanoma patients are currently excluded from novel clinical trials because of their immunodeficient status, the potential drug interactions and the effects of HIV infection on the safety and activity of the investigational agents. These findings and the lack of curative therapy for HIV infected melanoma patients with metastatic disease emphasize the urgent need to define novel effective therapies for this subgroup of melanoma patients.

In vitro and in vivo evidences suggest a major role of immune checkpoint molecules in the pathogenesis and clinical progression of HIV infection. PD-1/PD-L1, CTLA-4, TIM-3, LAG-3 and TIGIT are higher expressed on the lymphocytes of HIV-positive as compared to HIV-negative patients [6-12]. However, the role of immune checkpoint molecules as well as the potential application of immune checkpoint targeting strategies in HIV disease still needs to be better defined.

In this article, firstly, we will describe the role of CTLA-4, PD-1, PD-L1, TIM-3, LAG-3 and TIGIT during HIV infection. Secondly, we will summarize the most relevant clinical evidences utilizing immune checkpoint blockade for the treatment of metastatic melanoma patients. Lastly, we will discuss the potential implications as well as the potential application of immune checkpoint-based immunotherapy in patients with melanoma and HIV.


Many in vitro and in vivo studies have been performed to define the interactions between HIV disease and immune checkpoint molecules. PD-1, PD-L1, CTLA-4, TIM-3, LAG-3 and TIGIT have been involved in chronic viral persistence and are usually used as a marker to define exhausted T cells during HIV infection (Fig. 1) [6-12]. In addition, T-cell exhaustion markers such as PD-1, TIM-3 and LAG-3, measured prior to antiretroviral therapy, are often used to strongly predict time of viremia rebound [9].

CTLA-4 gene polymorphisms and their involvement in chronic viral infection were described for the first time in Hepatitis B Virus (HBV) infection [13]. In HIV subjects, CTLA-4 is significantly higher on CD4+ T cells as compared to cells from normal donors. Furthermore, CTLA-4 levels are negatively correlated with both CD4+ T cell number and CD4/CD8 ratio, while are positively correlated with HIV viral load and disease progression [14, 15]. CTLA-4 is also expressed by HIV-specific CD4+ T cells although its levels change based on the timing of HIV infection [14-16]. Specifically, CTLA-4 upregulation on CD4+ T cells is followed by its downregulation during disease progression. CTLA-4 downregulation is mediated by the Negative Regulatory Factor (Nef), a protein involved in HIV survival and viral replication into T cells [16].

The axis of PD-1 and PD-L1 can also modulate HIV-specific T cell response although contrasting data are reported in the literature about the correlation of PD-1 expression with number of CD4+ T cells, HIV viral load and disease progression. PD-1 is overexpressed on both CD4+ and CD8+ T cells of HIV patients. In those, CD4+ and CD8+ T cells express significantly higher levels of PD-1 as compared to cells from normal donors [17, 18]. In addition, PD-1 levels are negatively correlated with CD4+ T cell number as well as with CD4/CD8 ratio, while are positively correlated with both HIV viral load and disease progression [17-20]. PD-1 levels on CD4+ T cells are also negatively associated with the viral replication in vivo [21] although Chomont et al. reported that infected CD4+ T cells co-expressing PD-1 might represents a major reservoir of HIV [22]. Lastly, PD-L1 is significantly elevated on monocytes and B cells in the peripheral blood of HIV-infected individuals as compared to HIV-negative controls. Its expression negatively correlated with the number of CD4+ T cells and its levels are associated with both viral load and disease progression [23].

Fig. (1). Immune checkpoint molecule expression in HIV infection. Immune checkpoint molecules can influence HIV chronic persistence by inhibiting immune system activation and elimination of HIV infected cells.

Several mechanisms can regulate PD-1 and PD-L1 expression in T cells from HIV infected patients. The common gamma-chain cytokines including IL-2, IL-7, IL-15 and IL-21 upregulate both PD-1 and PD-L1 in vitro [24]. In addition, the accessory HIV protein Nef upregulates PD-1 through p38 MAPK-dependent mechanism [25].

The immune checkpoints TIM-3, LAG-3 and TIGIT have been also investigated in the pathogenesis of HIV. TIM-3 expression on CD8+ T cells is increased in HIV patients as compared to uninfected subjects. Furthermore, TIM-3 upregulation positively correlates with HIV viral load and CD38 expression, while it is negatively associated with CD4+ T cell number [26]. Co-expression of TIM-3 and PD-1 is associated with a more severe exhaustion of T cells during HIV infection in vitro [27]. The ligand of TIM-3, galectin-9, is rapidly released during acute HIV infection and galectin-9-TIM-3 crosstalk contributes to persistent T cell dysfunction [28]. In contrast to this data, Hoffmann et al. showed that TIM-3 expression might be a protective biomarker in some infected subjects because of its association with a delayed HIV disease progression [12].

LAG-3 expression on CD8+ T cells is associated with HIV plasma viral load, but not with number of CD4+ T cell [12]. Upregulation of LAG-3 on both CD4+ and CD8+ T cells is correlated with HIV disease progression and a prolonged antiretroviral therapy can reduce its expression. In addition, the overexpression of LAG-3 on T cells or the stimulation of LAG-3 on T cells leads to a reduction of T cell responses [29].

TIGIT is upregulated on CD8+ T cells during HIV infection and the co-expression of PD-1 and TIGIT positively correlates with HIV disease progression [10]. Tauriainen et al. showed that an increased TIGIT expression in vitro correlates with a decreased functional capacity of HIV-specific CD8+ T cells [30]. Lastly, LAG-3 and TIGIT, alone or in combination with PD-1, positively correlate with an increased number of CD4+ T cells that harbor an integrated HIV DNA [11].

Few experimental evidences have been testing the potential applicability of immune checkpoint inhibitors in HIV infection and contrasting results are reported in the literature. Blocking of both PD-1 and CTLA-4 in HIV-1-specifìc CD4+ and CD8+ T cells leads to a recovery of cell proliferation and a cytokine production in vitro [19]. Furthermore, CTLA-4 blockade by an anti-CTLA-4 mAb increases CD4+ T cell proliferation and augments HIV-specific CD4+ T cell function in vitro [14, 15]. In a simian immunodeficiency virus (SIV)-infected macaque model, administration of an anti-CTLA-4 mAb decreases viral replication of the infected subjects while it is associated with an increased viral replication at mucosal site and no benefit in terms of plasma viral load and survival [31, 32]. Into the clinical setting just few case reports have been reported. Wightman et al. have recently shown that treatment with anti-CTLA-4 mAb in a metastatic melanoma patients could reactivate HIV from latency [33]. Sabbatino et al. have been reported a melanoma tumor response associated with a decreased viral replication and an increased number of CD4+ T cells in a patient with both HIV infection and metastatic melanoma during treatment with an antiretroviral therapy and an anti-CTLA-4 mAb [34]. Blockade of PD-1 has also been reported in chronic viral infection. In vitro blockade of PD-1, in patients affected by HBV, leads to an increased T cell survival as well as to an increased cytokine production, especially in patients with HIV co-infection [35]. Moreover, Trautmann et al. reported that PD-1 blockade enhances the capacity of HIV-specific CD8+ T cells to survive and proliferate leading to an increased production of cytokines and cytotoxic molecules in response to cognate antigen in vitro [19]. Even more, in vitro stimulation of CD28 in combination with PD-1 blockade synergistically increases HIV-specific CD4+ T cell proliferation [8]. Lastly, in a SIV-infected macaque model, blockade of PD-1 by an anti-PD-1 mAb increases the number of virus-specific CD4+ T cells and memory B cells as well as the levels of envelope-specific antibodies. These immunological effects are associated with the lack of side effects and a significantly increase of OS of the treated SIV-infected macaques [36].

Besides CTLA-4 and PD-1, also blockade of other checkpoint molecules has been tested in chronic viral infection. In vitro blockade of TIM-3 signaling pathway enhances the cytotoxic capabilities of HIV specific CD8+ T cells from chronic progression by increasing their functions and their ability to suppress HIV infection of CD4+ T cells [37]. Furthermore, the ex vivo blockade of LAG-3 significantly augments HIV-specific CD4+ and CD8+ T cell responses [29]. Lastly, in vivo combinatorial blockade of PD-L1 and TIGIT restores viral-specific CD8+ T cell effector response [10].


The introduction of immune checkpoint inhibitors into clinical setting has drastically changed the survival of metastatic melanoma patients. Several mAbs have been developed to inhibit the interaction of immune regulatory checkpoint molecules CTLA-4 and PD-1 with their ligands CD80 or CD86 and PD-L1 or PD-L2, respectively [38]. As a result, T cells can proliferate and elicit the host immune response against cancer cells.

Ipilimumab (Yervoy, Bristol-Myers Squibb), a fully human immunoglobulin G1 (IgG1), targeting CTLA-4, was the first mAb to demonstrate a survival benefit in patients with metastatic melanoma. In a Phase III randomized clinical trial (MDX010-020) administration of ipilimumab in combination with glycoprotein 100 (gp100) peptide increased OS as compared to gp100 vaccination alone (10.1 versus 6.4 months) [39]. In another Phase III randomized clinical trial (CA184-024), ipilimumab in combination with dacarbazine demonstrated a significantly longer OS as compared to dacarbazine alone (11.2 versus 9.1 months) [40]. An update analysis has confirmed the survival benefit of ipilimumab in metastatic melanoma patients showing an 18.2% of 5-year survival rate for patients treated with ipilimumab plus dacarbazine as compared to 8.8% of patients treated with placebo plus dacarbazine [41]. Even more administration of ipilimumab at 10 mg/kg significantly increased OS of melanoma patients as compared to standard dose of 3 mg/kg (15.7 versus 11.5 months) [42]. However, the relevant results obtained with ipilimumab have been mitigated following the publication of the clinical trials data of the anti-PD-1 mAbs, nivolumab (Opdivo, Bristol-Myers Squibb) and pembrolizumab (Keytruda, Merck), in metastatic melanoma patients.

In a Phase III randomized clinical trial (CheckMate 066) administration of nivolumab, a fully human IgG4 anti-PD-1, improved 1- and 2-year OS rate as compared to standard chemotherapy with dacarbazine in previously untreated patients with metastatic melanoma without BRAF mutation (73.0% versus 41.0% at 1 year and 56.7% versus 26.7% at 2 years) [43, 44]. In another Phase III randomized clinical trial (CheckMate 037) nivolumab demonstrated a higher percentage of overall response rate (ORR) as compared to investigator’s choice chemotherapy in patients with metastatic melanoma who experienced disease progression following anti-CTLA-4 or BRAF inhibitor treatment (31.7% vs 10.6%) [45]. In a Phase II randomized clinical trial (KEYNOTE-002) administration of pembrolizumab, a humanized IgG4 anti-PD-1, at two different doses, was compared to investigator’s choice chemotherapy in metastatic melanoma patients who experienced disease progression after treatment with ipilimumab and/or BRAF inhibitor and/or MEK inhibitor. The 6-month progression free survival (PFS) rate was 34% and 38% for pembrolizumab at 2 and 10 mg/Kg, respectively, while it was only 16% for the chemotherapy group [46]. Median OS was 13.4 and 14.7 months for 2 and 10 mg/kg of pembrolizumab, respectively, while it was 11.0 months for chemotherapy. Eighteen-month OS rates were 40%, 44% and 36% and 24-month rates were 36%, 38% and 30% [47]. Lastly, in a Phase III randomized clinical trial (KEYNOTE-006), pembrolizumab, at two different schedules of treatment (10 mg/Kg every two or three weeks), demonstrated an improvement in PFS (12-month PFS 39% and 38% versus 19%; 24-month PFS 31% and 28% versus 14%) and OS (1-year OS rate 74% and 68% versus 59%; 2-year OS rate 55% and 55% versus 43%) as compared to ipilimumab alone [48, 49].

Immune checkpoint blockade using anti-PD-L1 mAbs is another promising approach for the treatment of melanoma patients with metastatic disease. BMS-956559 (Bristol-Myers Squibb), a fully human IgG4, was the first anti-PD-L1 mAb to show objective tumor responses in patients with solid tumors [50]. In addition, anti-PD-L1 mAbs such as Atezolizumab (MPDL3280A, Roche Genentech), Durvalumab (MEDI4736, Astrazeneca) and Avelumab (MSB00107185, EMD Serono/Merck KGaA/Pfizer) are currently tested in clinical trials and their results are expected soon. Moreover, several ongoing clinical trials are now testing blockade of different checkpoint inhibitors such as LAG-3, TIM-3 or TIGIT, alone or in combination with anti-PD-1/PD-L1 drugs, in metastatic melanoma patients.

Both anti-CTLA-4 and anti-PD-1/PD-L1 mAbs are revolutionizing the clinical approach to melanoma patients regardless the mutational status. However, as we have previously described, the efficacy of this novel immunotherapeutic strategy is limited to up to 40% of treated patients and there is still the need to identify potential predictive biomarkers of treatment response. Several biomarkers are under investigation including PD-L1, PD-L2, FAS, HLA class I and HLA class II antigen expression, immune checkpoints LAG-3, TIM-3, IDO, OX40, CD137 and CD40 expression, tumor infiltrating lymphocytes (TIL), CD4+, CD8+, granzyme B+, CD56+ and FOXP3+ cells, secreted molecules IL-2, IFN-γ, IL-10, IL-4, CXCL9, CXCL10, CCL5, cancer cell mutational load, antigenic peptide expression, gene expression and TCR signaling analysis. So far, none of these biomarkers including PD-L1 expression has been shown to play a major role as a predictive biomarker of response to immune checkpoint molecule based immunotherapy. In a large meta-analysis, which summarized the results of clinical trials utilizing anti-PD-1 mAbs in malignant diseases including melanoma, PD-L1 expression by tumor cells correlated with ORR. However, in both PD-L1 positive and negative tumors clinical response rates and an increased OS were reported [51]. As a result, PD-L1 expression might be used to identify patients that benefit more from anti-PD-1 based immunotherapy but it cannot be used to exclude patients from the treatment with this type of therapy. The combination of different immune checkpoint inhibitors is currently tested as an alternative strategy to increase the ORR and OS of treated melanoma patients.

In a randomized Phase III clinical trial (CheckMate 067), administration of ipilimumab and nivolumab was compared to single agent alone (ipilimumab or nivolumab) in previously untreated melanoma patients. The median PFS was 11.5 months in the nivolumab-plus-ipilimumab group as compared to 6.9 months for nivolumab alone and 2.9 months for ipilimumab alone [52]. The median OS had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 months in the nivolumab group and 19.9 months in the ipilimumab group. The 3-years OS was higher in the nivolumab-plus-ipilimumab group as compared to nivolumab and ipilimumab groups (58% versus 52% and 34%, respectively). However, a higher rate of grade 3-4 immune-related toxicities was reported in the combination group as compared to single agents alone (59% in the nivolumab-plus-ipilimumab group, 21% in the nivolumab group and 28% in the ipilimumab group) [53].

Lastly, immune checkpoint inhibitors have been tested not only in the metastatic setting of melanoma patients, but also as an adjuvant strategy following surgery for high risk melanoma patients. In a Phase III randomized clinical trial the anti-CTLA-4 mAb ipilimumab increased the 5-years rates of recurrence-free survival (40.8% versus 30.3%), OS (65.4% versus 54.4%) and distant metastasis–free survival (48.3% versus 38.9%) as compared to placebo in high-risk stage III melanoma patients [54]. However, also in this case, side effects were not irrelevant. Recently, another Phase III randomized clinical trial compared 1-year administration of nivolumab with ipilimumab in completely resected stage III-IV melanoma patients. Nivolumab significantly improved 12-month rate of recurrence-free survival as compared to ipilimumab (70.5% versus 60.8%), with a reduced incidence of treatment-related grade 3-4 adverse events (14.4% versus 45.9%) [55].


The implementation of immune checkpoint-based immunotherapy is completely revolutionizing the clinical approach to cancer patients. In melanoma, a tumor that for many years has shown high rate of deaths because of its resistance to standard therapy, administration of both anti-CTLA-4 and anti-PD-1 mAbs significantly increases response rates, PFS and OS of the treated patients [38-53].

Nevertheless, in cancer patients carrying a chronic viral infection such as HIV, the anti-tumor activity of these molecules has not been extensively evaluated and clinical trials are still warranted. Some clinical cases showed clinical and immunological response to checkpoint inhibitors in melanoma patients with HIV, HBV or Hepatitis C Virus (HCV) infections [33, 34, 56-60]. Moreover, in a retrospective analysis of 44 patients affected by metastatic tumors (including 29 melanoma patients) and concurrent solid organ transplant, HIV, HBV or HCV infections, the administration of anti-PD-1/PD-L1 mAbs appeared to have clinical activity in the absence of adverse effect on the viral control [61]. Recently, another retrospective study evaluated the efficacy of immune checkpoint blockade in metastatic melanoma patients with concomitant HIV infection, pointing out similar results [62]. Globally, these data provide evidences about the efficiency of immune checkpoint inhibitors as treatment of melanoma and HIV disease. As previously described, HIV infection plays a crucial role in determining the worst prognosis of HIV-infected cancer patients because of the induction of a chronic and progressive immunodeficient status [4]. The latter causes the inability to mount an effective host immune response and the persistence and/or the progressive expression of different immune checkpoint molecules (CTLA-4, PD-1/PD-L1, TIM-3, LAG-3, TIGIT) lastly leads to an immune exhausted phenotype [63-65].

Ideally, treatment of metastatic cancer in patients with HIV should not further compromise immune competence, interact adversely with antiretroviral agents or increase the risk of tumor development. This hypothesis is supported by the results obtained from two recently published Phase I/II clinical trials. In a first trial, patients with advanced hepatocellular carcinoma were treated with nivolumab including those affected by HCV and HBV infection. The results demonstrate that infected patients have similar outcomes in terms of tumor response and safety profile as compared to non-infected subjects [66]. In a second trial, patients with squamous cell carcinoma of the anal canal were treated with nivolumab. A sub-analysis confirmed nivolumab efficacy and safe in both HIV-negative and HIV-positive patients [67, 68]. However, these preliminary data are referred to small cohorts of cancer patients with chronic viral infections and they have to be interpreted cautiously.

Several Phase I/II clinical trials (NCT02408861, NCT03304093, NCT02595866) testing the administration of checkpoint inhibitors, alone or in combination, in patients with HIV and advanced solid tumors are currently ongoing. Their results will shed some light on the efficacy and safety of this therapeutic strategy in this subgroup of cancer patients which has always been excluded from previous clinical trials. In conclusion, there is an urgent need to design new clinical trials in order to determine the effectiveness of treatment with checkpoint molecule inhibitors for the treatment of HIV and/or HIV-related cancer patients.


CTLA-4  = Cytotoxic T Lymphocyte Antigen-4;
gp100  = Glycoprotein 100;
HBV  = Hepatitis B Virus;
HCV  = Hepatitis C Virus;
HIV  = Human Immunodeficiency Virus;
HLA  = Human Leukocyte Antigen;
IgG1  = Human Immunoglobulin G1
LAG-3  = Lymphocyte-Activation Gene-3;
mAb  = Monoclonal Antibody;
Nef  = Negative Regulatory Factor;
ORR  = Overall Response Rate
OS  = Overall Survival;
PD-1  = Programmed Death-1;
PD-L1  = Programmed Death-Ligand-1;
PFS  = Progression Free Survival;
SIV  = Simian Immunodeficiency Virus;
TIGIT  = T cell Immunoreceptor with Ig and ITIM Domains;
TIM-3  = T-cell Immunoglobulin and Mucin-domain Containing-3.


FS and AM conceived and designed the work. All authors contribute to write the manuscript. All authors read and approved the final manuscript.


Not applicable.


PA has/had a consultant/advisory role for BMS, Roche-Genentech, MSD, Novartis, Ventana, Amgen, and Array. He received also research grants from BMS, Roche-Genentech, Ventana, and Array. SP received research grants from Roche-Genentech and Astrazeneca.


Declared none.


[1] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49(6): 1374-403.
[2] Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148(10): 728-36.
[3] Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc 2012; 87(10): 991-1003.
[4] Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States. J Clin Oncol 2015; 33(21): 2376-83.
[5] Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 2017; 14(8): 463-82.
[6] Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10(1): 29-37.
[7] Kaufmann DE, Walker BD. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention Journal of immunology (Baltimore, Md : 1950) 2009; 182(10): 5891-7.
[8] Kassu A, Marcus RA, D’Souza MB, et al. Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol 2010; 185(5): 3007-18.
[9] Hurst J, Hoffmann M, Pace M, et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun 2015; 6: 8495.
[10] Chew GM, Fujita T, Webb GM, et al. TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathog 2016; 12(1): e1005349.
[11] Fromentin R, Bakeman W, Lawani MB, et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog 2016; 12(7): e1005761.
[12] Hoffmann M, Pantazis N, Martin GE, et al. Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. PLoS Pathog 2016; 12(7): e1005661.
[13] Thio CL, Mosbruger TL, Kaslow RA, et al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004; 78(20): 11258-62.
[14] Kaufmann DE, Kavanagh DG, Pereyra F, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8(11): 1246-54.
[15] Zaunders JJ, Ip S, Munier ML, et al. Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J Virol 2006; 80(20): 10162-72.
[16] El-Far M, Ancuta P, Routy J-P, et al. Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation. J Gen Virol 2015; 96(Pt 6): 1463-77.
[17] Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443(7109): 350-4.
[18] Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203(10): 2281-92.
[19] Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12(10): 1198-202.
[20] D'Souza M, Fontenot AP, Mack DG, Lozupone C, Dillon S, Meditz A, et al. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. Journal of immunology (Baltimore, Md : 1950) 2007; 179(3): 1979-87.
[21] Salisch NC, Kaufmann DE, Awad AS, et al. Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. Journal of immunology (Baltimore, Md : 1950) 2010; 184(1): 476-87.
[22] Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15(8): 893-900.
[23] Trabattoni D, Saresella M, Biasin M, et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 2003; 101(7): 2514-20.
[24] Kinter AL, Godbout EJ, McNally JP, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. Journal of immunology (Baltimore, Md : 1950) 2008; 181(10): 6738-46.
[25] Muthumani K, Choo AY, Shedlock DJ, et al. Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol 2008; 82(23): 11536-44.
[26] Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008; 205(12): 2763-79.
[27] Zhang ZN, Zhu ML, Chen YH, et al. Elevation of Tim-3 and PD-1 expression on T cells appears early in HIV infection, and differential Tim-3 and PD-1 expression patterns can be induced by common gamma -chain cytokines. Biomed Res Int 2015.
[28] Tandon R, Chew GM, Byron MM, et al. Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers. AIDS Res Hum Retroviruses 2014; 30(7): 654-64.
[29] Tian X, Zhang A, Qiu C, et al. The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects. J Immunol 2015; 194(8): 3873-82.
[30] Tauriainen J, Scharf L, Frederiksen J, et al. Perturbed CD8(+) T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci Rep 2017; 7: 40354.
[31] Hryniewicz A, Boasso A, Edghill-Smith Y, et al. CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 2006; 108(12): 3834-42.
[32] Cecchinato V, Tryniszewska E, Ma ZM, et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. Journal of immunology (Baltimore, Md : 1950) 2008; 180(8): 5439-47.
[33] Wightman F, Solomon A, Kumar SS, et al. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS 2015; 29(4): 504-6.
[34] Sabbatino FF, Marra A, Fusciello C, et al. Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infection. J Transl Med 2016; 14(Suppl. 1): 15.
[35] Sherman AC, Trehanpati N, Daucher M, et al. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir. AIDS Res Hum Retroviruses 2013; 29(4): 665-72.
[36] Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458(7235): 206-10.
[37] Sakhdari A, Mujib S, Vali B, et al. Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PLoS One 2012; 7(7): e40146.
[38] Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 2015; 33(17): 1974-82.
[39] Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711-23.
[40] Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517-26.
[41] Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015; 33(10): 1191-6.
[42] Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017; 18(5): 611-22.
[43] Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372(4): 320-30.
[44] Two-Year Survival and Safety Update in Patients (pts) with Treatment-Naïve Advanced Melanoma (MEL) Receiving Nivolumab (NIVO) or Dacarbazine (DTIC) in CheckMate-066. Presented at the Society for Melanoma Research 2015 International Congress; November 18-21, 2015; San Francisco, CA.. 2015. Available at: nivolumab-survival-benefit-sustained-in-long-term-melanoma-data
[45] Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4): 375-84.
[46] Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16(8): 908-18.
[47] Hamid O, Puzanov I, Dummer R, et al. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Annals of Oncology 2016.
[48] Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26): 2521-32.
[49] Schacter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. J Clin Oncol 2016; (17): 31601-X.
[50] Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26): 2455-65.
[51] Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015; 10(6): e0130142.
[52] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1): 23-34.
[53] Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377(14): 1345-56.
[54] Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375(19): 1845-55.
[55] Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017.
[56] Burke MM, Kluger HM, Golden M, Heller KN, Hoos A, Sznol M. Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. J Clin Oncol 2011; 29(32): e792-4.
[57] Ruzevick J, Nicholas S, Redmond K, Kleinberg L, Lipson EJ, Lim M. A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain. Case Rep Oncol Med 2013.
[58] Davar D, Wilson M, Pruckner C, Kirkwood JM. PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. Case Rep Oncol Med 2015.
[59] Tomsitz D, Hein R, Biedermann T, Kohlmeyer J. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab. J Eur Acad Dermatol Venereol 2017.
[60] Le Garff G, Samri A, Lambert-Niclot S, et al. Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. AIDS 2017; 31(7): 1048-51.
[61] Rai R, Ezeoke OM, McQuade JL, Zimmer L, Koo C, Park JJ, et al. 1148PDImmunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C. Annals of Oncology 2017; 28
[62] Heppt MV, Schlaak M, Eigentler TK, et al. Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. Ann Oncol 2017.
[63] McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001; 410(6831): 980-7.
[64] Streeck H, Nixon DF. T cell immunity in acute HIV-1 infection. J Infect Dis 2010; 202(Suppl. 2): S302-8.
[65] Chang JJ, Altfeld M. Innate immune activation in primary HIV-1 infection. J Infect Dis 2010; 202(Suppl. 2): S297-301.
[66] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389(10088): 2492-502.
[67] Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017; 18(4): 446-53.
[68] Yanik EL, Kaunitz GJ, Cottrell TR, et al. Association of HIV status with local immune response to anal squamous cell carcinoma: Implications for immunotherapy. JAMA Oncol 2017; 3(7): 974-8.